{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CRS+-+Cytokine+Release+Syndrome&page=2",
    "query": {
      "condition": "CRS - Cytokine Release Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CRS+-+Cytokine+Release+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T12:05:29.609Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04371393",
      "title": "MSCs in COVID-19 ARDS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mesenchymal Stromal Cells",
        "Remestemcel-L",
        "Acute Respiratory Distress Syndrome",
        "COVID"
      ],
      "interventions": [
        {
          "name": "Remestemcel-L",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2020-04-30",
      "completion_date": "2022-01-02",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 21,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04371393"
    },
    {
      "nct_id": "NCT06703216",
      "title": "Pre-emptive Anakinra for Cytokine Event Reduction",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-Acute Lymphoblastic Leukemia",
        "CAR-T Cell Therapy",
        "Cytokine Release Syndrome",
        "Immune Effector Cell Associated Neurotoxicity Syndrome",
        "Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome"
      ],
      "interventions": [
        {
          "name": "Anakinra (Kineret®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin McNerney",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-10",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06703216"
    },
    {
      "nct_id": "NCT04433078",
      "title": "RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Storm",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-06-22",
      "completion_date": "2021-04-13",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433078"
    },
    {
      "nct_id": "NCT04374149",
      "title": "Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytokine Release Syndrome",
        "COVID19"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Prisma Health-Upstate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-04-30",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04374149"
    },
    {
      "nct_id": "NCT04356690",
      "title": "Etoposide in Patients With COVID-19 Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-05-08",
      "completion_date": "2022-07-01",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04356690"
    },
    {
      "nct_id": "NCT06806033",
      "title": "A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-03-05",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 33,
      "location_summary": "Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06806033"
    },
    {
      "nct_id": "NCT04540120",
      "title": "Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Cytokine Release Syndrome"
      ],
      "interventions": [
        {
          "name": "dapansutrile capsules",
          "type": "DRUG"
        },
        {
          "name": "placebo capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olatec Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-09-24",
      "completion_date": "2022-07-28",
      "has_results": false,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 9,
      "location_summary": "Coral Gables, Florida • Fort Lauderdale, Florida • Hialeah, Florida + 6 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04540120"
    },
    {
      "nct_id": "NCT05306080",
      "title": "Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "CRS - Cytokine Release Syndrome",
        "HLH"
      ],
      "interventions": [
        {
          "name": "Tadekinig alfa (IL-18BP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-04-17",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05306080"
    },
    {
      "nct_id": "NCT04603742",
      "title": "Anakinra, COVID-19, Cytokine Storm",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Cytokine Storm",
        "Mechanical Ventilation Complication"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-12",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-25",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04603742"
    },
    {
      "nct_id": "NCT04433546",
      "title": "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Coronavirus",
        "Hypoxic Respiratory Failure",
        "Hypoxemic Respiratory Failure",
        "Respiratory Complication",
        "Respiratory Insufficiency",
        "Cardiac Dysfunction",
        "Pneumonia",
        "Pulmonary Edema",
        "Pulmonary Inflammation",
        "Respiratory Failure",
        "Cytokine Storm",
        "COVID 19",
        "SARS-CoV-2",
        "Cardiac Event",
        "Cardiac Complication",
        "Cardiac Failure",
        "Cardiac Infarct"
      ],
      "interventions": [
        {
          "name": "Pemziviptadil (PB1046)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose (10 mg) Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-15",
      "completion_date": "2020-12-02",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-07-24T12:05:29.609Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433546"
    }
  ]
}